Wheatley, Roseanna C.
Kilgour, Elaine
Jacobs, Timothy
Lamarca, Angela
Hubner, Richard A.
Valle, Juan W. http://orcid.org/0000-0002-1999-0863
McNamara, Mairéad G. http://orcid.org/0000-0002-2272-3678
Article History
Received: 14 April 2021
Revised: 16 September 2021
Accepted: 4 October 2021
First Online: 18 October 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: RCW: no competing interests to declare. EK: no competing interests to declare. TJ: no competing interests to declare. AL: received travel and educational support from Ipsen, Pfizer, Bayer, AAA, SirtEx, Novartis, Mylan and Delcath; speaker honoraria from Merck, Pfizer, Ipsen, Incyte and AAA; advisory honoraria from EISAI, Nutricia Ipsen, QED and Roche; she is a member of the Knowledge Network and NETConnect Initiatives funded by Ipsen; all outside scope of this work. RAH has served on the advisory board for Roche, BMS, Eisai, Celgene, Beigene, Ipsen and BTG. He has received speaker fees from Eisai, Ipsen, Mylan and PrimeOncology, and has received travel and educational support from Bayer, BMS and Roche; all outside of the scope of this work. JWV received honoraria from Agios, AstraZeneca, Baxter, Genoscience Pharma, Hutchison Medipharma, Imaging Equipment Ltd (AAA), Incyte, Ipsen, Mundipharma EDO, Mylan, QED, Servier, Sirtex and Zymeworks; and grants, honoraria and non-financial support from NuCana, all outside of the scope of this work. MMN received research grant support from Servier, Ipsen and NuCana. She has received travel and accommodation support from Bayer and Ipsen and speaker honoraria from Pfizer, Ipsen, NuCana and Mylan. She has served on advisory boards for Celgene, Ipsen, Sirtex, Baxalta and Incyte; all outside of the scope of this work.